Related Experiment Video
Updated: Apr 7, 2026

05:16
Sleeve Gastrectomy in Mice using Surgical Clips
Published on: November 14, 2020
7.6K
Failed Surgical Weight Loss Does Not Necessarily Mean Failed Metabolic Effects
Ali Aminian1, Mohammad Jamal1, Toms Augustin1
11 Bariatric and Metabolic, Cleveland Clinic , Cleveland, Ohio.
Diabetes Technology & Therapeutics
|July 16, 2015
Summary
Even modest weight loss after bariatric surgery improves diabetes and heart health. This study shows significant benefits in blood sugar, blood pressure, and triglycerides for obese patients with diabetes.
Area of Science:
- Metabolic Surgery
- Bariatric Surgery Outcomes
- Diabetes Management
Background:
- The metabolic effects of bariatric surgery in patients with suboptimal weight loss are not well understood.
- Obesity and type 2 diabetes often require effective long-term management strategies.
Purpose of the Study:
- To assess the long-term clinical and metabolic outcomes in obese patients with diabetes following bariatric surgery with limited excess weight loss (≤25%).
Main Methods:
- A cohort of 31 obese patients with type 2 diabetes and ≤25% excess weight loss post-bariatric surgery were followed for a median of 6 years.
- Clinical outcomes including diabetes remission, improvement, weight loss, glycemic control, and cardiometabolic risk factors were evaluated.
Main Results:
- Diabetes remission or clinical improvement was observed in 65% of patients.
- A mean total weight loss of 7.0% was associated with significant reductions in fasting blood glucose and diabetes medication needs.
- Significant improvements were noted in systolic blood pressure and triglyceride levels.
Conclusions:
- Modest weight loss (5-10% of initial body weight) after bariatric surgery can significantly improve cardiometabolic risk factors in morbidly obese patients with diabetes.
- Weight-independent mechanisms of bariatric surgery may contribute to improved glycemic control.
Related Concept Videos
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
394
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
394
Endoscopic Procedures IV: Sigmoidoscopy and Laproscopy
1.1K
Sigmoidoscopy and laparoscopy are distinct medical procedures that enable physicians to internally inspect different parts of the GI tract. Although they serve different purposes, each is essential for diagnosing and, in some cases, treating various medical conditions.
Sigmoidoscopy
Sigmoidoscopy is a diagnostic procedure that uses a flexible sigmoidoscope equipped with a light source and camera to examine the rectum and sigmoid colon. The procedure involves inserting the tube through the anus...
Sigmoidoscopy
Sigmoidoscopy is a diagnostic procedure that uses a flexible sigmoidoscope equipped with a light source and camera to examine the rectum and sigmoid colon. The procedure involves inserting the tube through the anus...
1.1K
Peptic Ulcer Disease V: Surgical Management and Nursing Care
1.2K
Surgical management and nursing care are crucial in treating Peptic Ulcer Disease (PUD). Here is an organized and enhanced overview of the surgical interventions and the associated nursing care for PUD:
Surgical Interventions for Peptic Ulcer Disease
Surgical Interventions for Peptic Ulcer Disease
1.2K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
288
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
288

